What Are ‘Ozempic Feet?’ Doctors Explain Latest GLP-1 Side Effect From Weight Loss
Friday, July 17 – Some people using GLP-1 drugs for weight loss have reported changes in their feet. Image Credit: stockvisual/Getty
“Ozempic feet” is the latest anecdotal side effect of GLP-1 drugs for weight loss.
The unusual phenomenon is a result of rapid weight loss, which may cause foot pain, changes in shoe size, and a more bony appearance in the feet.
Study identifies patients with obesity most likely to benefit from GLP-1-based treatment
Friday, July 17 – Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A Mayo Clinic study offers a potential answer by identifying a distinct biological subtype of obesity that responds especially well to tirzepatide, a medication that mimics two naturally occurring hormones involved in appetite and blood sugar regulation, moving the field closer to precision medicine for obesity.
Rise of GLP-1s raises long-term affordability questions
Friday, July 17 – As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University study that analyzed national trends in GLP-1 use and spending between 2017 and 2022. These total payments included out-of-pocket costs paid by patients as well as payments from insurers, employers and government programs.
Ozempic-like drugs have more benefits to the body than just losing weight, meta-analysis shows
Friday, July 17 – A meta-analysis of 10 randomized controlled trials involving more than 23,000 participants, presented at the International Congress on Obesity (ICO 2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico (July 15–17), shows that the GLP-1 class of obesity drugs is associated with a marked reduction in systemic inflammation beyond its anti-obesity effects, potentially explaining how the drugs can reduce cardiovascular risk factors.
Eli Lilly invests in Oura to support patients on GLP-1 drugs
Saturday, July 18 – Eli Lilly on Wednesday made an equity investment in wearable ring startup Oura as the drugmaker looks for ways to support patients taking its GLP-1 medications.
An Oura spokesperson declined to share the size of …
Internet searches on weight-loss medications have increased 25-fold since the launch of GLP-1 drugs
Thursday, July 16 – Public interest in obesity medication has risen 25-fold since the launch of GLP-1 receptor agonist drugs, new research presented at the International Congress on Obesity (ICO2026) in Mexico City, Mexico, hosted by the World Obesity Federation (July 15–17) shows.
New GLP-1 Concern; FDA Sued by Health Groups; Over 750 Dead in Ebola Outbreak
Thursday, July 16 – (MedPage Today) — Note that some links may require registration or subscription.
A preprint study flagged signals of frailty in seniors taking the GLP-1 drug tirzepatide (Zepbound) for weight loss. (Reuters via Yahoo!)
The House passed a bill…
GLP-1s Good for Marriage Prospects? RFK Jr.’s Diabetes Ads Axed; CGMs for Toddlers
Thursday, July 16 – (MedPage Today) — GLP-1 drugs did not appear to improve diabetes patients’ job or marriage prospects, according to a working paper from the National Bureau of Economic Research. (Axios)
The U.S. by 2035 will have 57 million overweight individuals…
China’s Mindrank raises $52M series B to advance oral GLP-1
Thursday, July 16 – Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China.
The GLP‑1 disclosure dilemma: Should you tell a date you’re using Ozempic for weight loss?
Wednesday, July 15 – As a Gen Xer who lived through the “heroin chic” years, when skeletal models were celebrated for jutting bones and sallow skin, the recent popularity of the #Y2KSkinny trend fills me with dread.